OncoLoop: A Network-Based Precision Cancer Medicine Framework

Overview

Journal Cancer Discov

Specialty Oncology

Date 2022 Nov 14

PMID 36374194

Authors

Alessandro Vasciaveo

Juan Martin Arriaga

Francisca Nunes de Almeida

Min Zou

Eugene F Douglass

Florencia Picech

Maho Shibata

Antonio Rodriguez-Calero

Simone de Brot

Antonina Mitrofanova

Chee Wai Chua

Charles Karan

Ronald Realubit

Sergey Pampou

Jaime Y Kim

Stephanie N Afari

Timur Mukhammadov

Luca Zanella

Eva Corey

Mariano J Alvarez

Mark A Rubin

Michael M Shen

Andrea Califano

Cory Abate-Shen

Affiliations

Soon will be listed here.

Abstract

Significance: OncoLoop is a transcriptomic-based experimental and computational framework that can support rapid-turnaround coclinical studies to identify and validate drugs for individual patients, which can then be readily adapted to clinical practice. This framework should be applicable in many cancer contexts for which appropriate models and drug perturbation data are available. This article is highlighted in the In This Issue feature, p. 247.

Citing Articles

Molecular characterization of the sea lamprey retina illuminates the evolutionary origin of retinal cell types.

Wang J, Zhang L, Cavallini M, Pahlevan A, Sun J, Morshedian A Nat Commun. 2024; 15(1):10761.

PMID: 39737973 PMC: 11685597. DOI: 10.1038/s41467-024-55019-x.

Identification and Targeting of Regulators of SARS-CoV-2-Host Interactions in the Airway Epithelium.

Dirvin B, Noh H, Tomassoni L, Cao D, Zhou Y, Ke X bioRxiv. 2024; .

PMID: 39464067 PMC: 11507692. DOI: 10.1101/2024.10.11.617898.

Network analysis to identify driver genes and combination drugs in brain cancer.

Roshani F, Ahvar M, Ebrahimi A Sci Rep. 2024; 14(1):18666.

PMID: 39134610 PMC: 11319350. DOI: 10.1038/s41598-024-69705-9.

Computer-aided drug discovery strategies for novel therapeutics for prostate cancer leveraging next-generating sequencing data.

Zhang W, Huang R Expert Opin Drug Discov. 2024; 19(7):841-853.

PMID: 38860709 PMC: 11537242. DOI: 10.1080/17460441.2024.2365370.

A systematic review on the culture methods and applications of 3D tumoroids for cancer research and personalized medicine.

Kalla J, Pfneissl J, Mair T, Tran L, Egger G Cell Oncol (Dordr). 2024; 48(1):1-26.

PMID: 38806997 PMC: 11850459. DOI: 10.1007/s13402-024-00960-8.

References

Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, Gopalan A . Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014; 159(1):176-187. PMC: 4237931. DOI: 10.1016/j.cell.2014.08.016. View

Sartor O, de Bono J . Metastatic Prostate Cancer. N Engl J Med. 2018; 378(7):645-657. DOI: 10.1056/NEJMra1701695. View

Alvarez M, Shen Y, Giorgi F, Lachmann A, Ding B, Ye B . Functional characterization of somatic mutations in cancer using network-based inference of protein activity. Nat Genet. 2016; 48(8):838-47. PMC: 5040167. DOI: 10.1038/ng.3593. View

Aytes A, Giacobbe A, Mitrofanova A, Ruggero K, Cyrta J, Arriaga J . NSD2 is a conserved driver of metastatic prostate cancer progression. Nat Commun. 2018; 9(1):5201. PMC: 6281610. DOI: 10.1038/s41467-018-07511-4. View

Risom T, Langer E, Chapman M, Rantala J, Fields A, Boniface C . Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun. 2018; 9(1):3815. PMC: 6145927. DOI: 10.1038/s41467-018-05729-w. View

Alvarez M, Yan P, Alpaugh M, Bowden M, Sicinska E, Zhou C . Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'. Nat Genet. 2019; 51(10):1427-1428. PMC: 7256901. DOI: 10.1038/s41588-019-0509-5. View

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I . Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019; 116(23):11428-11436. PMC: 6561293. DOI: 10.1073/pnas.1902651116. View

Mishra V, Re D, Le Verche V, Alvarez M, Vasciaveo A, Jacquier A . Systematic elucidation of neuron-astrocyte interaction in models of amyotrophic lateral sclerosis using multi-modal integrated bioinformatics workflow. Nat Commun. 2020; 11(1):5579. PMC: 7642391. DOI: 10.1038/s41467-020-19177-y. View

Kruczek K, Ratterman M, Tolzien K, Sulo S, Lestingi T, Nabhan C . A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer. Br J Cancer. 2013; 109(7):1711-6. PMC: 3790181. DOI: 10.1038/bjc.2013.530. View

10.

Bush E, Ray F, Alvarez M, Realubit R, Li H, Karan C . PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens. Nat Commun. 2017; 8(1):105. PMC: 5524642. DOI: 10.1038/s41467-017-00136-z. View

11.

Floch N, Kinkade C, Kobayashi T, Aytes A, Lefebvre C, Mitrofanova A . Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res. 2012; 72(17):4483-93. PMC: 3432676. DOI: 10.1158/0008-5472.CAN-12-0283. View

12.

Ma J, Fong S, Luo Y, Bakkenist C, Shen J, Mourragui S . Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients. Nat Cancer. 2021; 2(2):233-244. PMC: 8248912. DOI: 10.1038/s43018-020-00169-2. View

13.

Zou M, Toivanen R, Mitrofanova A, Floch N, Hayati S, Sun Y . Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. Cancer Discov. 2017; 7(7):736-749. PMC: 5501744. DOI: 10.1158/2159-8290.CD-16-1174. View

14.

Douglass Jr E, Allaway R, Szalai B, Wang W, Tian T, Fernandez-Torras A . A community challenge for a pancancer drug mechanism of action inference from perturbational profile data. Cell Rep Med. 2022; 3(1):100492. PMC: 8784774. DOI: 10.1016/j.xcrm.2021.100492. View

15.

Son J, Ding H, Farb T, Efanov A, Sun J, Gore J . BACH2 inhibition reverses β cell failure in type 2 diabetes models. J Clin Invest. 2021; 131(24). PMC: 8670842. DOI: 10.1172/JCI153876. View

16.

Wang X, Kruithof-de Julio M, Economides K, Walker D, Yu H, Halili M . A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009; 461(7263):495-500. PMC: 2800362. DOI: 10.1038/nature08361. View

17.

Madisen L, Zwingman T, Sunkin S, Oh S, Zariwala H, Gu H . A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci. 2009; 13(1):133-40. PMC: 2840225. DOI: 10.1038/nn.2467. View

18.

Bruzzese F, Pucci B, Milone M, Ciardiello C, Franco R, Chianese M . Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Cell Death Dis. 2013; 4:e878. PMC: 3920938. DOI: 10.1038/cddis.2013.406. View

19.

Brichta L, Shin W, Jackson-Lewis V, Blesa J, Yap E, Walker Z . Identification of neurodegenerative factors using translatome-regulatory network analysis. Nat Neurosci. 2015; 18(9):1325-33. PMC: 4763340. DOI: 10.1038/nn.4070. View

20.

Bekes M, Langley D, Crews C . PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022; 21(3):181-200. PMC: 8765495. DOI: 10.1038/s41573-021-00371-6. View